Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 251 to 260 of 1514 total matches.

Metipranolol: A New Beta-blocker For Glaucoma

   
The Medical Letter on Drugs and Therapeutics • Oct 05, 1990  (Issue 828)
with the first few doses. The The Medical Letter, Vol. 32 (Issue 828) October 5, 1990, pp. 91-92 Copyright ...
Metipranolol hydrocholride 0.3% (OptiPranolol - Bausch & Lomb), a nonselective beta-adrenergic receptor blocking drug, was recently marketed of ophthalmic use to decrease intraolular pressure in ocular hypertension or chronic open-angle glaucoma. Beta-blockers available in the USA for treatment of glaucoma are listed in this article.
Med Lett Drugs Ther. 1990 Oct 5;32(828):91-2 |  Show IntroductionHide Introduction

Etidronate for Postmenopausal Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Dec 14, 1990  (Issue 833)
Letter, Vol. 32 (Issue 833) December 14, 1990, pp. 111-112 Copyright  The Medical Letter UNAUTHORIZED ...
Etidronate (e ti droe' nate) disodium (Didronel - Norwich Eaton), an oral bisphosphonate available for many years for treatment of Paget's disease (Medical Letter, 20:78, 1978), recently has also been used for treatment of postmenopausal osteoporosis.
Med Lett Drugs Ther. 1990 Dec 14;32(833):111-4 |  Show IntroductionHide Introduction

A Subdermal Progestin Implant For Long-Term Contraception

   
The Medical Letter on Drugs and Therapeutics • Mar 08, 1991  (Issue 839)
The Medical Letter, Vol. 33 (Issue 839) March 8, 1991, pp. 17-18 Copyright  The Medical Letter UNAUTHORIZED ...
The Norplant System (Wyeth-Ayerst) for subdermal delivery of the synthetic progestin levonorgestrel was recently approved by the US Food and Drug Administration for use as a long-term contraceptive.
Med Lett Drugs Ther. 1991 Mar 8;33(839):17-8 |  Show IntroductionHide Introduction

BCG For Bladder Cancer

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 1991  (Issue 841)
. Three vials of TheraCys cost the pharmacist $148.38 and one The Medical Letter, Vol. 33 (Issue 841 ...
BCG Live (TheraCys - Connaught) and BCG Vaccine U.S.P. (TiceBCG - Organon), freeze-dried suspensions of an attenuated strain of Mycobacterium bovis, were recently approved by the US Food and Drug Administration for intravesical treatment of primary or relapsed carcinoma in situ of the bladder, with or without associated papillary tumors. BCG is not recommended for treatment of papillary tumors occurring alone.
Med Lett Drugs Ther. 1991 Apr 5;33(841):29-30 |  Show IntroductionHide Introduction

Autologous Bone marrow Transplantation For Advanced Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • May 03, 1991  (Issue 843)
cancer who had a standard induction The Medical Letter, Vol. 33 (Issue 843) May 3, 1991, pp. 39-40 ...
The prognosis in breast cancer is generally poor for women with unresectable, locally advanced disease (inflammatory cancer or more than 10 positive lymph nodes) and for those with metastases. Autologous bone marrow transplantation - removing bone marrow from multiple sites under general anesthesia, giving high-dose chemotherapy with or without total body radiation, and reinfusing the bone marrow intravenously - is being tried in some of these patients.
Med Lett Drugs Ther. 1991 May 3;33(843):39-40 |  Show IntroductionHide Introduction

Gallium For Hypercalcemia of Malignancy

   
The Medical Letter on Drugs and Therapeutics • May 03, 1991  (Issue 843)
, Vol. 33 (Issue 843) May 3, 1991, pp. 41-42 Copyright  The Medical Letter UNAUTHORIZED FORWARDING ...
Gallium nitrate (Ganite - Fujisawa, USA), originally an anticancer drug, was recently marketed for treatment of cancer-associated hypercalcemia that has not responded to hydration. Other drugs used for treatment of hypercalcemia include furosemide (Lasix, and others), the bisphosphonate etidronate (Didronel IV), calcitonin (Calcimar), and plicamycin (Mithracin, formerly mithramycin) (RAB Schaiff et al, Clin Pharm, 8:108, 1989). Newer bisphosphonates are available in Europe.
Med Lett Drugs Ther. 1991 May 3;33(843):41-2 |  Show IntroductionHide Introduction

Altretamine For Ovarian Cancer

   
The Medical Letter on Drugs and Therapeutics • Aug 09, 1991  (Issue 850)
have The Medical Letter, Vol. 33 (Issue 850) August 9, 1991, pp. 76-77 Copyright  The Medical Letter ...
Altretamine (Hexalen - US Bioscience; Hexastat - Rh ne-Poulenc in Canada), formerly known only by its chemical name, hexamethylmelamine, was recently approved by the US Food and Drug Administration as a single agent for palliative oral treatment of persistent or recurrent ovarian cancer.
Med Lett Drugs Ther. 1991 Aug 9;33(850):76-7 |  Show IntroductionHide Introduction

Topical Drugs For Vaginal Candidiasis

   
The Medical Letter on Drugs and Therapeutics • Aug 23, 1991  (Issue 851)
% The Medical Letter, Vol. 33 (Issue 851) August 23, 1991, p. 81 Copyright  The Medical Letter UNAUTHORIZED ...
Many drugs, mostly imidazole derivatives, are marketed in the USA for topical treatment of vulvovaginal candidiasis, and a few are now available without a prescription.
Med Lett Drugs Ther. 1991 Aug 23;33(851):81 |  Show IntroductionHide Introduction

Fludarabine

   
The Medical Letter on Drugs and Therapeutics • Sep 20, 1991  (Issue 853)
, paresthesias, peripheral The Medical Letter, Vol. 33 (Issue 853) September 20, 1991, pp. 89-90 Copyright ...
Fludarabine phosphate (Fludara - Berlex), an analog of vidarabine (Vira-A), was recently approved by the U.S. Food and Drug Administration for treatment of patients with refractory chronic lymphocytic leukemia (CLL). The drug has not yet been marketed but is still available, as it has been for two years, through the National Cancer Institute.
Med Lett Drugs Ther. 1991 Sep 20;33(853):89-90 |  Show IntroductionHide Introduction

Intranasal Triamcinolone For Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • Dec 13, 1991  (Issue 859)
, but maximum The Medical Letter, Vol. 33 (Issue 859) December 13, 1991, pp. 116-117 Copyright  The Medical ...
An intranasal formulation of the corticosteroid triamcinolone (Nasacort - Rh ne- Poulenc Rorer) was recently approved by the US Food and Drug Administration for once-daily treatment of seasonal and perennial allergic rhinitis.
Med Lett Drugs Ther. 1991 Dec 13;33(859):116-7 |  Show IntroductionHide Introduction